Gain of pancreatic beta cell-specific SCD1 improves glucose homeostasis by maintaining functional beta cell mass under metabolic stress
Diabetologia · 2025
DOI: 10.1007/s00125-024-06343-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, 2025. Verfasst von Wenyue Yin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Stearoyl-CoA Desaturase, Glucose, Stress, Physiological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China, 2023 Taizhou Science and Technology Support Program (Social Development) Project, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
AIMS/HYPOTHESIS: The key pancreatic beta cell transcription factor v-maf musculoaponeurotic fibrosarcoma oncogene homologue A (MafA) is critical for the maintenance of mature beta cell function and phenotype. The expression levels and/or activities of MafA are reduced when beta cells are chronically exposed to diabetogenic stress, such as hyperglycaemia (i.e. glucotoxicity). Interventional targets and adjuvant therapies to abate MafA loss in beta cells may provide evidence to support the effective treatment of diabetes. In this study, we aimed to investigate the function of stearoyl-CoA desaturase 1 (SCD1) in the stabilisation of MafA expression and activity in order to maintain functional beta cell mass, with a view to suppressing the development of type 2 diabetes. METHODS: SCD1 expression levels were analysed in islets obtained from humans with type 2 diabetes, hyperglycaemic db/db mice, and a high-fat diet (HFD)-induced mouse model of diabetes. Pancreatic beta cell-specific Scd1 knockin (βSCD1KI) mice were generated to study the role of SCD1 in beta cell function and identity. The protein-to-protein interactions between SCD1 and MafA were detected in MIN6 and HEK293A cells. We used experiments including chromatin immunoprecipitation, cell-based ubiquitination assay and fatty acid composition analysis to investigate the specific molecular mechanism underlying the effect of SCD1 on the restoration of MafA and beta cell function under glucotoxic conditions. RESULTS: SCD1 expression was reduced in beta cells of humans with type 2 diabetes and in HFD-fed and db/db mice compared with healthy controls, which was attributed to glucotoxicity-induced Scd1 promoter histone deacetylation. Gain-of-function of SCD1 in beta cells improved insulin deficiency, glucose intolerance and beta cell dedifferentiation/transdifferentiation in the HFD-induced mouse model of diabetes. Mechanistically, SCD1 directly bound to the E3 ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) and stabilised nuclear MafA through interrupting MafA-HRD1 interactions in mouse islets and MIN6 cells, which inhibited the ubiquitination-mediated degradation of MafA. Moreover, the products of SCD enzyme reactions (mainly oleic acid) also alleviated glucotoxicity-mediated oxidative stress in MIN6 cells. CONCLUSIONS/INTERPRETATION: Our findings indicate that SCD1 stabilises beta cell MafA both in desaturase-dependent and -independent manners, thus improving glucose homeostasis under metabolic stress. This provides a potential novel target for precision medicine for the treatment of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Central Laboratory, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Taizhou, Jiangsu, China.
- Organ Transplant Center, Tianjin First Central Hospital, Nankai University, Tianjin, China.
- Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Nuclear Medicine, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
- Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu, China. yaqinzhang@njmu.edu.cn.
Förderung
- National Key Research and Development Program of China
- 2023 Taizhou Science and Technology Support Program (Social Development) Project
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- the Project Foundation of Taizhou School of Clinical Medicine affiliated to Nanjing Medical University
Zitieren
APA
Yin, W., Zou, S., Sha, M., Sun, L., Gong, H., Xiong, C., Huang, X., Wang, J., Zhang, Y., Li, X., Liang, J., Chang, X., Wang, S., Su, D., Guo, W., Zhang, Y., Wu, T., & Chen, F. (2025). Gain of pancreatic beta cell-specific SCD1 improves glucose homeostasis by maintaining functional beta cell mass under metabolic stress. Diabetologia. https://doi.org/10.1007/s00125-024-06343-w
Vancouver
Yin W, Zou S, Sha M, Sun L, Gong H, Xiong C, et al. Gain of pancreatic beta cell-specific SCD1 improves glucose homeostasis by maintaining functional beta cell mass under metabolic stress. Diabetologia. 2025. doi:10.1007/s00125-024-06343-w
BibTeX
@article{Yin2025,
author = {Yin, Wenyue and Zou, Suyun and Sha, Min and Sun, Liangjun and Gong, Haoqiang and Xiong, Can and Huang, Xinyue and Wang, Jianan and Zhang, Yuhan and Li, Xirui and Liang, Jin and Chang, Xiaoai and Wang, Shusen and Su, Dongming and Guo, Wanhua and Zhang, Yaqin and Wu, Tijun and Chen, Fang},
title = {Gain of pancreatic beta cell-specific SCD1 improves glucose homeostasis by maintaining functional beta cell mass under metabolic stress},
journal = {Diabetologia},
year = {2025},
doi = {10.1007/s00125-024-06343-w}
}
EUVIMED